(Total Views: 669)
Posted On: 11/10/2020 8:23:48 PM
Post# of 155733
The new PR strategy is definitely having an impact. NP mentioned that a new firm was on board. We have seen:
1. Two NP appearances on Fox News
2. Three to five (lost count) separate TV news stories on the Leronlimab trials at local hospitals. I remember one from Oregon, Houston, Los Angeles. All of these were quite recent and followed the same formula...explain the trial, name Cytodyn and Leronlimab, snippets from NP and a reference to the local hospital running trials. This is formulaic and smacks of an organized PR strategy (what a concept!).
3. This most recent video from New York television, clearly (an accurately) lining up Leronlimab as similar to Regeneron and Lilly MABs, while explaining the differences (we attack the storm, focus on severe and don't yet have EUA).
I commend all of these news stories for being pretty darn accurate. That is quite rare.
The acceptance of Dr. Patterson's paper is certainly timely. And, don't forget, Dr. Yang's was accepted in the past two weeks as well.
It has been a rough ride for the share price. But, we may be building a new base and certainly this positive, consistent scientific and television PR can't hurt.
1. Two NP appearances on Fox News
2. Three to five (lost count) separate TV news stories on the Leronlimab trials at local hospitals. I remember one from Oregon, Houston, Los Angeles. All of these were quite recent and followed the same formula...explain the trial, name Cytodyn and Leronlimab, snippets from NP and a reference to the local hospital running trials. This is formulaic and smacks of an organized PR strategy (what a concept!).
3. This most recent video from New York television, clearly (an accurately) lining up Leronlimab as similar to Regeneron and Lilly MABs, while explaining the differences (we attack the storm, focus on severe and don't yet have EUA).
I commend all of these news stories for being pretty darn accurate. That is quite rare.
The acceptance of Dr. Patterson's paper is certainly timely. And, don't forget, Dr. Yang's was accepted in the past two weeks as well.
It has been a rough ride for the share price. But, we may be building a new base and certainly this positive, consistent scientific and television PR can't hurt.
(9)
(0)
